Skip to main content

Table 3 Overall survival rates of patients

From: Effect of prior cancer on survival outcomes for patients with pancreatic adenocarcinoma: a propensity score analysis

Cancer type No Overall survival rates (%) HR (95% CI) p a
1-year (95% CI) 2-year (95% CI) 3-year (95% CI)
Whole cohort 9235 36.7(36.6–36.7) 18.7(18.6–18.7) 11.7(11.6–11.7)   
Without prior cancer 8797 36.8(36.7–36.9) 18.7(18.6–18.8) 11.7(11.6–11.8)   
Prostate cancer 126 35.6(35.3–35.8) 21.4(21.1–21.5) 13.3(13.1–13.5) 1.137(0.928–1.393) 0.171
Breast cancer 110 36.5(36.4–36.6) 16.6(16.5–16.7) 14.7 (14.6–14.8) 0.966(0.780–1.197) 0.749
Renal and bladder cancer 51 35.6(35.5–35.7) 21.4(21.3–21.5) 13.3(13.2–13.4) 1.004(0.732–1.376) 0.980
Colon and rectal cancer 43 30.2(30.1–30.3) 15.3(15.2–15.4) 12.3(12.2–12.4) 1.149(0.813–1.624) 0.382
Uterine cancer 24 41.8(41.6–42.0) 36.6(36.4–36.8) 36.6(36.4–36.8) 0.700(0.451–1.086) 0.165
Lung cancer 16 49.2(49.0–49.4) 16.4(16.2–16.6) 8.2(8.1–8.4) 0.865(0.531–1.408) 0.572
Small intestinal cancer 15 44.0(43.7–44.3) 11.7(11.5–11.9) 11.7(11.5–11.9) 0.948(0.533–1.687) 0.855
Oral cancer 13 51.9(51.6–52.2) 17.3(17.1–17.5) 0.0 0.976(0.544–1.752) 0.935
Gastric cancer 12 36.5(36.2–36.8) 0.0 0.0 1.150(0.571–2.318) 0.663
Hepatocellular cancer 8 37.5(37.2–37.8) 12.5(12.3–12.7) 12.5(12.3–12.7) 1.014(0.481–2.138) 0.971
Matched cohort 4818 35.1(35.0–35.2) 18.2(18.1–18.2) 11.7(11.7–11.7)   
Without prior cancer 4380 33.0(32.9–33.1) 18.2(18.1–18.3) 11.7(11.6–11.7)   
Prostate cancer 126 35.6(35.3–35.5) 21.4(21.1–21.5) 13.3(13.1–13.5) 0.967(0.708–1.318) 0.826
Breast cancer 110 36.5(36.4–36.6) 16.6(16.5–16.7) 14. (14.6–14.8) 0.927(0.751–1.145) 0.481
Renal and bladder cancer 51 35.6(35.5–35.7) 21.4(21.3–21.5) 13.3(13.2–13.4) 0.967(0.709–1.318) 0.826
Colon and rectal cancer 43 30.2(30.1–30.3) 15.3(15.2–15.4) 12.3(12.2–12.4) 1.107(0.788–1.557) 0.521
Uterine cancer 24 41.8(41.6–42.0) 36.6(36.4–36.8) 36.6(36.4–36.8) 0.676(0.439–1.041) 0.125
Lung cancer 16 49.2(49.0–49.4) 16.4(16.2–16.6) 8.2(8.048–8.352) 0.842(0.520–1.364) 0.504
Small intestinal cancer 15 44.0(43.7–44.3) 11.7(11.5–11.9) 11.7(11.5–11.9) 0.908(0.517–1.596) 0.739
Oral cancer 13 51.9(51.6–52.2) 17.3(17.1–17.5) 0.0 0.943(0.531–1.676) 0.840
Gastric cancer 12 36.5(36.2–36.8) 0.00 0.0 1.093(0.552–2.167) 0.781
Hepatocellular cancer 8 37.5(37.2–37.8) 12.5(12.3–12.7) 12.5(12.3–12.7) 0.982(0.471–2.010) 0.961
  1. CI Confidence interval
  2. pa-values represented the differences of overall survival rates between patients with certain kind of prior tumor and those without prior tumor